articl
provid
summari
inform
present
intern
symposium
influenza
respiratori
virus
organ
conven
macra
group
new
york
citi
ny
maui
hawaii
decemb
symposium
cosponsor
intern
societi
antivir
research
nation
institut
allergi
infecti
diseas
purpos
symposium
bring
togeth
lead
expert
review
statu
current
research
regard
respiratori
virus
provid
new
insight
epidemiolog
clinic
impact
detect
includ
rapid
diagnost
pathogenesi
manag
infect
emphasi
novel
approach
immun
antivir
treatment
meet
intend
benefit
work
field
multidisciplinari
approach
serv
forum
open
discuss
among
repres
academia
govern
industri
direct
futur
research
meet
chair
frederick
g
hayden
univers
virginia
usa
w
paul
glezen
baylor
colleg
medicin
usa
attend
particip
countri
invit
speaker
includ
jame
antczak
trimeri
usa
curti
carlson
biostar
decad
report
incid
acut
respiratori
tract
infect
increas
global
annual
rate
pneumonia
increas
person
year
age
han
et
al
year
ago
investig
ten
countri
around
world
estim
global
burden
respiratori
infect
children
selwyn
incid
acut
respiratori
infect
among
children
month
age
rang
new
episod
per
childweek
risk
rate
lower
respiratori
tract
infect
rang
new
episod
per
childweek
risk
children
spent
observ
week
acut
respiratori
tract
ill
observ
week
lower
respiratori
tract
ill
case
fatal
rate
vari
hospit
children
respiratori
syncyti
viru
rsv
main
pathogen
identifi
observ
studi
show
develop
countri
lower
respiratori
tract
infect
children
lead
caus
disabl
death
pelleti
et
al
paxton
et
al
howev
pattern
respiratori
viral
infect
depend
geograph
locat
season
syndrom
upper
versu
lower
respiratori
tract
age
set
ambulatori
versu
hospit
filipino
children
b
year
old
acut
lower
respiratori
infect
admit
hospit
viral
infect
confirm
ruutu
et
al
measl
influenza
viru
common
etiolog
identifi
measl
rsv
lead
caus
hospit
singapor
respiratori
viral
outbreak
among
hospit
infant
associ
rsv
infect
case
influenza
parainfluenza
virus
case
chew
et
al
rsv
outbreak
occur
mainli
dri
season
howev
season
rsv
infect
differ
part
world
exampl
gambia
rsv
outbreak
occur
raini
season
weber
et
al
kenya
respiratori
virus
demonstr
children
acut
respiratori
infect
hazlett
et
al
measl
rsv
parainfluenza
virus
piv
adenovirus
observ
rhinovirus
herp
simplex
enteroviru
also
associ
case
sever
acut
respiratori
infect
indian
children
year
age
hospit
acut
respiratori
tract
infect
diagnos
acut
bronchiol
virus
found
rsv
respons
case
bronchiol
parainfluenza
virus
next
common
respons
case
cherian
et
al
brazil
caus
acut
respiratori
tract
ill
investig
young
children
live
commun
period
arruda
et
al
respiratori
virus
isol
sampl
isol
rhinovirus
piv
enterovirus
adenovirus
herp
virus
influenza
virus
studi
rsv
detect
anoth
studi
brazil
rsv
respons
case
acut
respiratori
infect
hospit
children
sutmol
et
al
unit
state
nation
health
interview
survey
estim
annual
number
acut
respiratori
condit
age
group
includ
case
pneumonia
case
influenzalik
ill
vital
health
statist
onehalf
condit
medic
attend
children
year
age
children
year
age
annual
number
respiratori
condit
respect
proport
respiratori
condit
medic
attend
children
year
age
children
year
age
annual
number
school
day
lost
acut
respiratori
condit
estim
number
workloss
day
current
employ
adult
year
age
estim
demograph
social
factor
play
import
role
occurr
respiratori
viral
diseas
exampl
impact
respiratori
tract
infect
higher
lowincom
famili
popul
poor
social
condit
rate
document
rsv
hospit
seem
doubl
last
year
compar
similar
survey
carri
probabl
wider
applic
rapid
diagnost
assay
prospect
evalu
us
children
hospit
acut
respiratori
ill
rsv
recov
case
follow
parainfluenza
virus
influenza
p
glezen
person
commun
investig
neg
case
elderli
rate
hospit
pneumonia
increas
estim
adult
year
age
suffer
acut
respiratori
condit
diagnos
clinic
influenza
pneumonia
elderli
acut
respiratori
condit
medic
attend
despit
influenza
vaccin
rate
among
person
two
success
influenza
epidem
excess
mortal
occur
last
year
epidem
estim
result
excess
death
per
year
observ
show
respiratori
tract
infect
major
public
health
concern
among
age
group
develop
well
develop
countri
molecular
epidemiolog
yield
insight
critic
understand
novel
human
influenza
virus
emerg
viru
gene
pool
present
among
lower
anim
influenza
virus
abl
evad
host
immun
defens
applic
genom
establish
fundament
properti
influenza
virus
natur
reservoir
aquat
bird
primordi
sourc
influenza
virus
limit
number
host
specif
lineag
geograph
separ
influenza
virus
aquat
bird
evolutionari
stasi
transfer
speci
rapid
evolut
current
differ
influenza
ha
subtyp
nine
differ
na
subtyp
recogn
natur
ha
gene
key
factor
pathogen
avian
virus
subtyp
outbreak
mexico
kill
thousand
chicken
caus
strain
viru
acquir
pathogen
ha
polybas
amino
acid
sequenc
could
cleav
host
cell
enzym
highli
cleavabl
ha
also
occur
chicken
isol
hong
kong
outbreak
poultri
slaughter
chicken
duck
carri
viru
molecular
analysi
hong
kong
virus
reveal
gene
segment
evolv
rapidli
except
ha
gene
suggest
gene
present
domest
avian
speci
time
analysi
virus
isol
domest
poultri
hong
kong
outbreak
reveal
addit
influenza
virus
number
influenza
subtyp
includ
cocircul
bird
intern
gene
sequenc
homolog
quailhong
ahong
suggest
viru
could
sourc
intern
gene
pathogen
viru
hong
kong
evid
suggest
ha
gene
viru
hong
kong
may
deriv
influenza
viru
gees
section
genet
studi
viral
rna
recov
lung
sampl
soldier
die
indic
pandem
viru
kill
million
person
worldwid
similar
classic
subtyp
swine
virus
taubenberg
et
al
viru
possess
polybas
amino
acid
sequenc
connect
subunit
hemagglutinin
associ
high
pathogen
avian
influenza
virus
subtyp
sampl
recent
obtain
human
buri
permafrost
norway
studi
underway
determin
viral
rna
present
addit
sequenc
inform
differ
time
differ
wave
pandem
differ
part
world
requir
provid
understand
remark
pathogen
viru
effect
surveil
system
new
epidem
pandem
strain
influenza
essenti
order
provid
earli
warn
spread
variant
molecular
epidemiolog
essenti
power
tool
character
virus
detail
antigen
genotyp
analys
help
determin
evolut
recent
human
influenza
virus
septemb
influenza
antigen
variant
repres
identifi
china
antigen
analysi
reveal
viru
distinct
virus
circul
previou
year
moreov
viru
delet
three
nucleotid
ha
gene
genet
chang
confer
dramat
chang
antigen
novemb
variant
detect
patient
asia
africa
europ
north
america
consequ
includ
influenza
vaccin
recent
analysi
ha
influenza
viru
found
amino
acid
differ
viru
previou
subtyp
virus
use
marker
possibl
demonstr
origin
australia
viru
caus
epidem
japan
januari
korea
februari
appear
australia
subsequ
spread
northern
hemispher
sinc
two
antigen
genet
distinct
lineag
influenza
b
circul
two
influenza
b
viru
strain
relat
either
virus
relat
circul
worldwid
present
current
deriv
includ
recent
vaccin
virus
detect
asia
surveil
data
shown
strain
predomin
china
last
year
outbreak
occur
pediatr
popul
china
moreov
recent
strain
identifi
asian
countri
lack
preexist
immun
viru
western
popul
leav
mani
individu
suscept
infect
concern
potenti
global
spread
second
lineag
increas
new
improv
techniqu
molecular
biolog
enabl
develop
better
diagnost
tool
enhanc
understand
respiratori
viral
epidemiolog
exampl
multiplex
reversetranscriptas
polymeras
chain
reaction
enzym
hybrid
assay
rtpcreha
use
studi
epidemiolog
six
common
respiratori
virus
assay
hexaplex
detect
influenza
b
rsv
human
piv
type
previou
studi
report
sensit
assay
compar
cell
cultur
isol
fan
et
al
specif
publish
posit
neg
predict
valu
approxim
respect
sampl
children
admit
children
hospit
wisconsin
milwauke
novemb
octob
sign
symptom
respiratori
tract
infect
test
multiplex
rtpcreha
assay
respiratori
sampl
nasopharyng
swab
lesser
extent
nasal
wash
bronchoalveolar
lavag
approxim
children
test
moder
serious
ill
acut
chronic
diseas
immunocompromis
assay
yield
posit
result
children
evid
dual
viral
infect
virus
found
period
octob
june
among
viru
posit
infant
less
month
age
rsv
posit
influenza
piv
age
group
rsv
posit
equal
number
piv
influenza
made
rest
year
age
influenza
rsv
lead
pathogen
year
age
influenza
caus
hospit
piv
approxim
pneumonia
episod
equal
divid
three
virus
influenza
rsv
piv
immunocompromis
host
case
identifi
due
piv
infect
use
molecular
diagnost
method
show
epidemiolog
respiratori
virus
complex
impact
virus
greater
previous
recogn
discord
result
report
epidemiolog
viral
respiratori
diseas
immunocompromis
host
publish
seri
mani
differ
exist
type
sampl
case
definit
comorbid
protect
measur
immun
statu
season
studi
type
diagnost
assay
exampl
neutropen
patient
pneumonia
late
earli
etiolog
pneumonia
consid
unknown
case
recent
studi
indic
bmt
recipi
acut
respiratori
ill
infect
commun
respiratori
viru
onehalf
case
associ
pneumonia
associ
mortal
rate
approxim
depend
viru
type
consecut
case
patient
bmt
develop
viral
respiratori
infect
mortal
rate
rsv
piv
influenza
b
virus
adenoviru
cmv
seven
case
rhinoviru
infect
e
whimbley
person
commun
neutropenia
secondari
chemotherapi
acut
leukemia
also
risk
factor
sever
commun
respiratori
viru
infect
particularli
rsv
upper
respiratori
tract
infect
acut
rhinopharyng
lead
pneumonia
case
myelosuppress
present
observ
justifi
delay
chemotherapi
transplant
patient
suffer
runni
nose
activ
respiratori
tract
symptom
common
upper
respiratori
tract
complic
respiratori
viru
infect
includ
acut
otiti
media
otiti
media
effus
acut
sinus
main
etiolog
predispos
agent
human
rhinoviru
rsv
human
coronavirus
adenovirus
parainfluenza
virus
influenza
virus
enterovirus
less
commonli
document
import
period
commun
activ
tradit
associ
viral
infect
syndrom
document
viru
isol
serolog
method
nucleic
acid
amplif
techniqu
enabl
frequent
detect
human
rhinovirus
coronavirus
provid
new
insight
etiolog
sinus
otiti
media
sever
studi
establish
tempor
associ
respiratori
viru
infect
otiti
media
children
respiratori
virus
recov
middl
ear
fluid
children
acut
otiti
media
case
cultur
case
immunoassay
case
rtpcr
recent
studi
use
rtpcr
found
evid
human
rhinoviru
rsv
human
coronaviru
infect
children
acut
otiti
media
et
al
implic
find
medic
manag
otiti
still
uncertain
sinc
specif
therapi
current
avail
influenza
remain
determin
whether
earli
antivir
treatment
acut
uri
prevent
develop
otiti
otiti
media
effus
common
childhood
diseas
without
clear
etiolog
although
typic
occur
episod
acut
otiti
media
estim
threefourth
case
acut
otiti
media
children
follow
otiti
media
effus
suggest
infect
play
major
role
respiratori
virus
detect
middl
ear
effus
cultur
case
rtpcr
et
al
frequent
recogn
one
rhinoviru
although
unclear
whether
detect
viral
rna
indic
persist
activ
replic
residu
rna
trap
secret
radiograph
evid
sinus
frequent
natur
experiment
common
cold
realiti
common
cold
viral
rhinosinus
use
rtpcr
virus
often
rhinovirus
found
sinu
sampl
adult
patient
acut
sinus
et
al
taken
togeth
studi
indic
human
rhinoviru
infect
associ
approxim
onehalf
acut
sinus
adult
onethird
otiti
media
children
epidemiolog
surveil
data
establish
relationship
morbid
mortal
circul
certain
respiratori
virus
influenza
epidem
well
recogn
caus
excess
mortal
particularli
elderli
rsv
activ
link
excess
hospit
mortal
young
children
also
elderli
nicholson
et
al
han
et
al
among
elderli
hospit
acut
cardiopulmonari
event
influenzalik
ill
approxim
rsv
infect
frequenc
compar
influenza
case
among
highli
influenza
vaccin
popul
death
rate
among
patient
hospit
rsv
high
falsey
et
al
data
suggest
rsv
elderli
patient
comorbid
caus
mani
hospit
death
influenza
influenza
vaccin
wide
util
rhinoviru
infect
also
underrecogn
pathogen
elderli
prospect
studi
subject
year
age
acut
upper
respiratori
infect
surveil
found
viru
infect
among
subject
rhinoviru
document
viru
posit
case
coronavirus
influenza
b
rsv
nicholson
et
al
lower
respiratori
symptom
complic
upper
respiratori
infect
observ
elderli
patient
live
home
among
elderli
patient
rhinoviru
sole
pathogen
median
durat
ill
day
lower
respiratori
tract
symptom
confin
bed
lower
respiratori
tract
symptom
frequent
patient
comorbid
data
emphas
respiratori
virus
influenza
major
caus
infect
morbid
elderli
patient
cystic
fibrosi
respiratori
virus
also
major
caus
pulmonari
complic
prospect
surveil
studi
among
children
cystic
fibrosi
nasopharyng
sampl
collect
start
cold
detect
viral
rna
rtpcr
bacteri
cultur
month
observ
children
suffer
cold
collinson
et
al
picornavirus
detect
sampl
rhinovirus
children
experienc
frequent
cold
evid
diseas
progress
judg
clinic
score
chang
fev
well
frequent
colon
pathogen
respiratori
tract
bacteria
recent
studi
shown
respiratori
viru
infect
precipit
acut
exacerb
asthma
across
age
group
nicholson
et
al
gern
et
al
folkert
et
al
lead
hospit
death
johnston
et
al
episod
acut
asthma
schoolchildren
associ
respiratori
viru
infect
case
virus
detect
rhinovirus
overal
children
experienc
averag
eight
cold
per
year
associ
four
five
asthma
exacerb
studi
children
infant
admit
hospit
wheez
ill
produc
similar
result
rsv
human
rhinoviru
togeth
account
hospit
admiss
sl
johnston
person
commun
adult
asthma
exacerb
associ
viru
infect
major
rhinovirus
nicholson
et
al
unfortun
current
antivir
therapi
proven
valu
remain
determin
whether
earli
antivir
therapi
rhinoviru
cold
might
reduc
likelihood
asthma
exacerb
abil
influenza
virus
undergo
rapid
unpredict
antigen
chang
given
viru
promin
place
among
emerg
reemerg
diseas
occurr
human
case
six
death
caus
influenza
viru
hong
kong
rais
concern
next
pandem
could
immin
base
analysi
poultri
sampl
shown
prior
time
epidem
virus
circul
poultri
farm
live
bird
market
hong
kong
analysi
virus
isol
human
outbreak
reveal
eight
rna
gene
segment
virus
avian
origin
ha
gene
close
relat
eurasian
lineag
virus
antigen
analysi
reveal
two
antigen
group
possess
correspond
genet
chang
encod
potenti
glycosyl
site
amino
acid
one
two
group
na
protein
virus
share
delet
amino
acid
stalk
region
discuss
section
pathogen
recov
hong
kong
appear
intern
gene
avian
viru
quail
perhap
avian
viru
gees
epidemiolog
studi
indic
transmiss
primarili
poultri
human
ineffici
recent
experi
chicken
suggest
transmiss
among
poultri
fecalor
probabl
aerosol
whether
occur
respiratori
droplet
fecalor
rout
human
unclear
human
human
transmiss
may
occur
limit
number
case
new
human
case
detect
sinc
poultri
cull
took
place
decemb
nevertheless
concern
remain
virus
may
pose
reemerg
threat
time
futur
reason
uniqu
virul
hong
kong
viru
human
uncertain
virus
isol
chicken
human
possess
hemagglutinin
molecul
multipl
basic
amino
acid
adjac
ha
cleavag
site
find
characterist
virul
avian
influenza
virus
observ
fact
viru
lethal
chicken
consist
presumpt
insert
allow
cellular
proteas
cleav
hemagglutinin
enabl
viru
spread
viscer
site
outsid
respiratori
tract
howev
extrapulmonari
dissemin
viru
document
human
case
hong
kong
four
human
isol
inocul
balbc
mice
viru
replic
well
mous
lung
virus
lethal
mice
replic
multipl
organ
show
differ
pattern
virul
lethal
dose
intermedi
associ
rel
low
mortal
brain
invas
associ
diseas
progress
lethal
observ
mice
infect
viru
replic
lung
viral
antigen
detect
smooth
muscl
brain
thu
strain
hong
kong
viru
compet
instanc
neurotrop
without
prior
adapt
mammalian
host
experi
shown
challeng
poultri
contain
ha
modifi
delet
polybas
aminoacid
sequenc
safe
vaccin
poultri
nonpathogen
influenza
viru
induc
antibodi
virus
challeng
virul
strain
viru
titer
lung
undetect
replic
occur
brain
group
receiv
vaccin
anoth
vaccin
strain
influenza
develop
util
baculoviru
express
vector
system
subunit
vaccin
contain
purifi
genet
engin
version
hemagglutinin
protein
preclin
data
demonstr
vaccin
protect
chicken
diseas
death
follow
challeng
lethal
dose
parent
viru
addit
vaccin
shown
induc
crossprotect
ahong
kong
infect
phase
clinic
trial
low
dose
purifi
subunit
vaccin
shown
good
toler
initi
antibodi
respons
detect
volunt
elisa
western
blot
assay
infrequ
neutral
assay
dose
escal
studi
ongo
characterist
immun
influenza
well
known
exhibit
subtypevari
specif
reduc
effect
succeed
natur
occur
viru
variant
prolong
durat
well
demonstr
immun
present
reoccurr
virus
immun
present
earli
exposur
marker
infect
remain
neg
activ
mucos
surfac
couch
et
al
immun
mediat
share
characterist
antibodi
hemagglutinin
neuraminidas
either
igg
iga
serum
secret
antihemagglutinin
antibodi
inhibit
adsorpt
viru
contribut
inhibit
releas
infect
cell
major
function
antineuraminidas
antibodi
inhibit
viral
releas
spread
infect
impair
dowdl
et
al
human
studi
infant
born
mother
high
level
neutral
antibodi
protect
longer
period
thu
demonstr
valu
passiv
immun
direct
toward
subunit
puck
et
al
increas
antineuraminidas
antibodi
result
vaccin
associ
reduc
amount
viru
nasal
secret
find
consist
concept
neuraminidas
activ
couch
et
al
variou
antibodi
quantit
relat
occurr
infect
ill
note
serum
neutral
nasal
secret
neutral
serum
antineuraminidas
nasal
secret
neuraminidas
antibodi
mediat
reduc
sever
infect
increas
titer
antibodi
couch
person
commun
thu
antibodi
modal
appear
capabl
contribut
immun
serum
igg
antiha
antibodi
import
mediat
base
studi
indic
igg
domin
antibodi
lower
respiratori
secret
deriv
serum
sinc
major
infect
consid
initi
small
particl
aerosol
deposit
viru
equal
nasopharynx
lower
respiratori
tract
infect
lower
respiratori
tract
lower
nasopharynx
serum
igg
antibodi
ha
would
first
line
defens
infect
couch
et
al
recent
studi
immun
deriv
mostli
anim
model
recent
studi
iga
knockout
mous
differ
infect
respons
mice
without
iga
antibodi
serum
secret
suggest
antibodi
requir
protect
mbawuik
unpublish
data
studi
influenza
mice
recent
focus
role
specif
lymphocyt
cytokin
immun
confirm
earlier
studi
cytotox
lymphocyt
ctl
occur
lower
airway
appear
primari
mechan
recoveri
viru
infect
cell
control
pneumonia
via
perforin
fasmedi
cell
destruct
mechan
knockout
mice
clear
either
defici
anim
recov
near
normal
fashion
contrast
absent
mark
impair
recoveri
infect
eichelberg
et
al
scherl
et
al
topham
doherti
cytokin
studi
show
domin
interferon
gamma
lung
infect
number
cytokin
also
present
could
contribut
diseas
recoveri
sarawar
et
al
kelso
et
al
overal
larg
number
factor
describ
contribut
inflammatori
respons
control
viru
replic
indic
recoveri
process
complex
studi
lymphocyt
human
shown
cell
mediat
cytotox
cell
exhibit
cytotox
ro
memori
cell
di
et
al
mbawuik
person
commun
level
cytotox
quantit
group
young
adult
elderli
adult
shown
young
adult
exhibit
signific
cytotox
wherea
occurr
among
elderli
individu
errat
find
might
contribut
suscept
complic
influenza
mbawuik
et
al
difficulti
provid
data
human
compar
inbr
mice
relat
methodolog
interferon
gamma
spot
form
cell
appear
accept
substitut
ctl
respons
recent
mhc
peptidespecif
tetram
use
precis
quantit
memori
cell
mcmichael
ocallaghan
develop
technolog
permit
human
studi
role
ctl
function
influenza
infect
diseas
rsv
singlestrand
negativesens
envelop
rna
viru
replic
varieti
cell
vitro
howev
human
rsv
replic
appear
restrict
respiratori
epitheli
cell
rsv
antigen
detect
ciliat
cell
also
submucosa
rsv
fusion
protein
respons
syncytia
format
give
viru
name
delag
et
al
g
protein
cell
attach
motif
extent
replic
small
airway
unknown
bronchiol
infant
young
children
bronchiol
character
atelectasi
hyperinfl
increas
airway
resist
mechan
lead
narrow
airway
includ
unfavor
mechan
infant
lung
epitheli
damag
submucos
edema
bronchiolar
reactiv
stark
et
al
microscop
rsv
infect
immunocompet
children
associ
epitheli
cell
injuri
bronchiol
desquam
lumin
plug
mucu
eosinophil
materi
squamou
metaplasia
submucos
edema
often
promin
neutrophil
uncommon
alveoli
rel
spare
giant
cellssyncytia
infrequ
immunocompromis
host
giant
cell
pneumonia
syncytia
commonli
found
along
inflammatori
infiltr
contain
neutrophil
epitheli
damag
produc
rsv
appear
due
direct
viral
cytopath
effect
mechan
upregul
chemotact
factor
product
multipl
cytokin
noah
becker
arnold
et
al
renzi
et
al
smyth
et
al
earli
age
hospit
observ
viral
replic
higher
sustain
day
primari
infect
confirm
primari
infect
associ
greatest
risk
sever
diseas
howev
reinfect
rsv
occur
episod
throughout
life
henderson
et
al
anim
model
mainli
cotton
rat
mous
demonstr
immun
f
protein
provid
greater
protect
reinfect
immun
g
protein
intern
protein
bovin
model
suppress
effect
matern
transfer
antibodi
anim
protect
effect
passiv
transfer
antibodi
demonstr
circul
neutral
antibodi
titer
human
matern
antibodi
appear
provid
partial
protect
seriou
diseas
rsvspecif
immun
respons
reduc
risk
subsequ
infect
involv
lower
respiratori
tract
bone
marrow
solid
organ
transplant
patient
sever
rsv
infect
prolong
rsv
shed
describ
hivinfect
infant
thu
cell
mediat
immun
play
major
role
clear
viru
deplet
cell
mous
lead
prolong
rsv
shed
hand
infus
larg
number
rsvspecif
cytotox
tcell
caus
sever
diseas
mous
model
rsv
infect
observ
may
relev
earli
effort
protect
infant
formalininactiv
vaccin
vaccin
immunogen
judg
antibodi
rise
lymphoprolif
respons
rsv
howev
natur
exposur
rsv
result
sever
ill
usual
high
percentag
children
hospit
bronchiol
pneumonia
age
seriou
ill
would
expect
eosinophilia
predomin
airway
affect
children
aberr
immun
respons
natur
infect
prior
exposur
formalin
inactiv
vaccin
presum
differ
pattern
pulmonari
cytokin
respons
found
mice
given
differ
vaccin
expos
rsv
mice
immun
formalinkil
vaccin
respons
character
mainli
eosinophil
wherea
natur
infect
associ
interferon
g
lung
wildtyp
rsv
infect
induc
gener
cytokin
pattern
import
viral
clearanc
inactiv
subunit
vaccin
shown
mainli
pattern
jackson
scott
konig
et
al
johnson
et
al
present
individu
protein
particularli
f
g
live
vector
antigen
present
would
predict
follow
respons
lead
enhanc
diseas
mediat
respons
rodent
recent
studi
suggest
uniqu
g
protein
may
stimul
eosinophilia
observ
indic
immun
rsv
face
import
immunolog
hurdl
children
three
major
parainfluenza
viru
piv
serotyp
design
type
piv
endem
sometim
caus
spring
epidem
piv
type
caus
fall
epidem
altern
year
piv
frequent
isol
like
caus
diseas
infant
immunocompromis
host
high
frequenc
reinfect
usual
less
sever
first
infect
evid
protect
immun
seen
strike
differ
viru
replic
live
vaccin
challeng
immunolog
compar
previous
natur
infect
children
like
influenza
viru
sialic
acid
receptor
thought
piv
cellular
recognit
site
piv
fusion
protein
undergo
cleavag
activ
piv
like
rsv
replic
superfici
epitheli
cell
respiratori
tract
bud
apic
cell
antibodi
two
major
surfac
protein
name
hemagglutininneuraminidas
protein
hn
fusion
protein
f
confer
protect
data
experiment
parainfluenza
shown
import
mucos
iga
antibodi
protect
respiratori
infect
virusspecif
iga
transcytosi
across
epitheli
cell
may
interfer
viru
matur
piv
caus
croup
laryng
probabl
replic
major
airway
piv
similar
rsv
caus
lower
respiratori
tract
infect
contrast
rsv
infect
seem
unlik
major
immunolog
mediat
compon
piv
ill
enhanc
natur
diseas
observ
administr
kill
vaccin
respiratori
virus
particularli
adenoviru
rsv
influenza
known
infect
replic
lower
respiratori
tract
epithelium
contrast
abil
rhinovirus
infect
lower
respiratori
tract
controversi
rhinoviru
type
detect
rtpcr
bronchoalveolar
lavag
obtain
experiment
infect
volunt
howev
contamin
sampl
rhinoviru
upper
airway
could
exclud
gern
et
al
insitu
hybrid
detect
rhinovir
genom
rna
discrimin
cellular
infect
contamin
upper
respiratori
tract
demonstr
presenc
viru
within
bronchial
epitheli
cell
bronchial
biopsi
ten
experiment
infect
subject
fraenkel
et
al
rhinoviru
detect
bronchial
epithelium
four
subject
sampl
taken
day
post
infect
bate
et
al
contrast
viru
detect
biopsi
taken
challeng
data
strongli
suggest
rhinoviru
capabl
replic
lower
airway
epithelium
often
occur
natur
condit
remain
determin
nonasthmat
person
undergo
rhinovir
infect
develop
princip
upper
respiratori
symptom
infrequ
exhibit
lower
respiratori
symptom
rhinovirusinduc
asthma
exacerb
nasal
aspir
children
increas
level
neutrophil
myeloperoxydas
increas
nasal
wash
level
also
correl
airway
hyperreact
asthmat
subject
experiment
infect
rhinoviru
type
grunberg
et
al
teran
et
al
result
suggest
neutrophil
involv
inflammatori
respons
rhinoviru
role
lower
respiratori
tract
infect
unclear
eosinophil
major
basic
protein
increas
nasal
secret
rhinoviru
infect
asthmat
children
increas
level
eosinophil
cation
protein
also
observ
sputum
asthmat
subject
undergo
experiment
rhinoviru
infect
grunberg
et
al
eosinophil
found
increas
number
airway
asthmat
person
experiment
rhinoviru
infect
suggest
eosinophil
infiltr
crucial
element
patholog
lead
exacerb
asthma
fraenkel
et
al
addit
lymphocyt
infiltr
occur
lower
upper
respiratori
tract
epithelium
submucosa
experiment
rhinoviru
cold
vivo
studi
demonstr
hrv
infect
respiratori
epitheli
cell
induc
receptor
e
arruda
person
commun
regul
hrv
infect
may
play
role
retent
activ
intraepitheli
lymphocyt
eosinophil
import
eosinophil
infiltr
factor
regul
express
may
therefor
repres
target
therapeut
intervent
eosinophil
infiltr
observ
asthmat
subject
viral
infect
may
also
result
epitheli
cell
product
cytokin
chemokin
direct
action
eosinophil
recruit
activ
rant
level
increas
nasal
aspir
children
virusinduc
exacerb
asthma
hrvinfect
bronchial
epitheli
cell
invitro
condit
johnston
find
need
confirm
rel
import
asthmat
normal
subject
investig
degre
redund
among
cytokin
function
suggest
even
one
import
molecul
function
could
block
molecul
may
fulfil
similar
role
render
treatment
aim
one
specif
molecul
ineffect
johnston
molecular
virolog
techniqu
also
appli
enhanc
diagnosi
influenza
viru
infect
influenza
season
rtpcr
influenza
viru
compar
serolog
cultur
patient
influenzalik
ill
countri
sampl
cultur
rtpcr
combin
nose
throat
swab
overal
case
cultur
posit
show
fourfold
greater
antibodi
titer
rise
rtpcr
posit
patient
posit
three
test
patient
posit
singl
test
rtpcr
serolog
cultur
eight
viru
type
subtyp
inform
concord
test
data
show
rtpcr
reason
rapid
highli
reliabl
test
detect
influenza
capabl
enhanc
sensit
detect
influenza
sever
rapid
assay
influenza
b
viru
detect
avail
develop
time
data
compar
sensit
specif
test
lack
moreov
util
test
elderli
highrisk
popul
critic
determin
reach
final
conclus
concern
util
test
clinic
practic
role
guid
antivir
therapi
studi
necessari
unit
state
three
commerci
avail
rapid
diagnost
test
approv
one
directigen
flu
colorimetr
immunoassay
detect
nucleoprotein
influenza
virus
anoth
one
optic
immunoassay
base
properti
light
reflect
thin
film
amplif
assay
allow
detect
nucleoprotein
influenza
b
virus
influenza
oia
biostar
assay
test
season
specimen
obtain
group
patient
fever
influenzalik
symptom
less
durat
patient
recruit
commun
rang
age
month
year
type
number
specimen
vari
patient
averag
specimen
collect
per
patient
viru
isol
cell
cultur
perform
avail
specimen
compar
cultur
sensit
rapid
assay
vari
throat
swab
nasopharyng
swab
nasal
aspir
sputum
patient
posit
cultur
type
sampl
consid
proven
influenza
assay
rel
sensit
specimen
type
throat
swab
nasopharyng
swab
sputum
nasal
aspir
investig
sandwich
immunoassay
use
monoclon
antibodi
direct
typespecif
nucleoprotein
influenza
b
virus
develop
recent
goldlabeledopticalreadoutassay
roch
laboratori
germani
perform
test
compar
viru
isol
mdck
cell
season
sampl
throat
swab
perform
children
influenzalik
ill
sensit
test
compar
cultur
specif
cultur
neg
goldlabeledopticalreadoutassay
posit
test
pcr
posit
influenza
rna
observ
suggest
enhanc
sensit
preliminari
result
test
encourag
studi
adult
elderli
necessari
new
rapid
prototyp
test
use
sandwich
assay
technolog
target
conserv
epitop
present
earli
infect
develop
target
could
protein
intern
membran
protein
repres
virion
protein
howev
membran
protein
difficult
extract
aqueou
solut
assay
target
readili
extract
typespecif
nucleoprotein
influenza
b
virus
possess
surfac
glycoprotein
neuraminidas
activ
thathydrolyz
substrat
contain
alphaketosiad
link
nacetylneuramin
acid
modifi
molecul
coupl
chromogen
design
produc
novel
neuraminidas
substrat
select
fit
influenza
neuraminidas
activ
site
chromogen
portion
cleav
neuraminidas
enzymat
activ
precipit
yield
blue
color
extract
viru
addit
reagent
incub
done
h
clinic
studi
done
season
use
throat
swab
patient
reveal
specif
sensit
compar
cultur
test
modifi
improv
sensit
shorten
procedur
min
howev
new
assay
test
larg
number
clinic
sampl
result
specimen
nasal
wash
yet
avail
influenza
strategi
immun
respons
although
rel
inexpens
increasingli
util
inactiv
influenza
vaccin
suffer
number
disadvantag
particular
induc
respons
limit
durabl
induc
limit
crossstrain
protect
contraind
individu
sever
egg
allergi
less
effect
frail
older
adult
complic
influenza
sever
one
strategi
improv
immun
respons
use
adjuv
iscom
immunostimul
complex
cagelik
structur
contain
differ
exogen
nonrepl
antigen
iscom
present
system
induc
ctl
respons
induc
antibodi
even
presenc
neutral
antibodi
iscom
influenza
vaccin
studi
macaqu
shown
superior
classic
vaccin
term
antibodi
tcell
respons
protect
iscom
vaccin
contain
viru
provid
superior
antibodi
respons
chicken
data
current
avail
protect
preliminari
clinic
studi
use
differ
iscom
prepar
fail
demonstr
clear
benefit
human
develop
abandon
present
coldadapt
influenza
vaccin
given
intranas
multipl
theoret
advantag
induct
mucos
immun
induct
cytotox
lymphocyt
respons
protect
upper
respiratori
tract
broader
perhap
durabl
immun
respons
addit
intranas
vaccin
easier
administ
intramuscular
inject
new
antigen
variant
rapidli
produc
use
genet
reassort
coldadapt
donor
strain
wild
type
viru
coldadapt
influenza
vaccin
use
aann
bann
arbor
virus
reproduc
infecti
attenu
transmiss
genet
stabl
prolong
shed
induc
protect
immun
children
adult
combin
inactiv
vaccin
report
increas
protect
elderli
placebocontrol
phase
iii
trial
conduct
assess
efficaci
trival
coldadapt
vaccin
caivt
children
given
one
dose
two
dose
cultureconfirm
influenza
two
consecut
season
vaccin
modifi
second
season
adapt
circul
strain
contain
viru
differ
predomin
circul
viru
year
children
enrol
vaccin
group
placebo
group
children
receiv
two
dose
year
among
children
seroneg
baselin
percentag
show
posit
hai
antibodi
respons
defin
fourfold
greater
increas
titer
rang
three
vaccin
strain
first
dose
second
dose
vaccin
gener
well
toler
associ
slight
excess
rhinorrhea
year
overal
efficaci
cultureconfirm
influenza
belsh
et
al
frequenc
confirm
influenza
year
influenza
influenza
b
among
placebo
recipi
vaccin
group
influenza
influenza
b
among
vaccine
sever
cultureposit
influenza
ill
markedli
attenu
year
new
drift
variant
appear
product
vaccin
caus
four
case
influenza
ill
caivt
provid
protect
efficaci
vaccin
ill
due
influenza
wuhanlik
viru
sydneylik
viru
result
show
vaccin
provid
solid
protect
homolog
wild
type
viru
drift
variant
repres
vaccin
addit
vaccin
provid
protect
influenza
associ
otiti
media
lower
respiratori
tract
diseas
placebocontrol
studi
caivt
also
conduct
last
season
healthi
work
adult
endpoint
includ
incid
influenzalik
ill
defin
day
least
two
influenzarel
symptom
sever
influenzalik
ill
day
symptom
upper
respiratori
tract
infect
febril
upper
respiratori
tract
infect
outbreak
period
caivt
vaccin
significantli
reduc
day
sever
influenzalik
ill
day
febril
upper
respiratori
tract
infect
number
overal
day
miss
work
reduc
influenzalik
ill
subject
trial
attempt
document
etiolog
ill
affect
person
dna
immun
dna
vaccin
highli
purifi
bacteri
plasmid
dna
vector
contain
promot
element
drive
transcript
translat
code
sequenc
antigen
interest
although
precis
mechan
action
remain
controversi
gener
accept
purifi
dna
taken
cell
antigen
synthes
insid
cell
neosynthesi
antigen
insid
host
cell
lead
associ
antigen
class
ii
mhc
molecul
migrat
cell
surfac
present
cytotox
lymphocyt
helper
cell
manner
dna
vaccin
abl
elicit
immun
respons
similar
attenu
live
viral
vaccin
addit
novel
mean
mhc
class
antigen
present
dna
vaccin
offer
sever
advantag
dna
thermal
stabl
plasmid
persist
time
site
inocul
respons
may
durabl
induc
protein
vaccin
dna
vaccin
associ
viral
vectorinduc
immun
respons
dampen
immun
respons
target
antigen
context
influenza
vaccin
dna
produc
egg
may
requir
annual
revaccin
adjuv
may
improv
immun
respons
dna
vaccin
number
mechan
includ
improv
effici
transfect
dna
improv
target
dna
specif
cell
type
activ
recruit
antigen
present
cell
protect
dna
degrad
anim
aluminum
adjuv
alum
aluminum
phosphat
improv
antibodi
respons
increas
plasmid
protein
express
util
dna
vaccin
technolog
obtain
vical
inc
merck
co
inc
develop
influenza
dna
vaccin
idv
encod
hemagglutinin
ha
current
ongo
phase
clinic
trial
center
immun
research
john
hopkin
school
public
health
preclin
test
ha
dna
vaccin
gener
hemagglutin
inhibit
respons
hai
speci
test
includ
mice
ferret
guinea
pig
african
green
rhesu
monkey
protect
follow
challeng
seen
mice
follow
littl
mg
ha
dna
protect
seen
singl
inject
mice
gene
np
appear
provid
crossstrain
protect
preliminari
data
two
ongo
doubleblind
phase
studi
analyz
first
studi
idv
evalu
adult
random
receiv
three
dose
mg
ha
dna
placebo
subject
boost
commerci
inactiv
influenza
vaccin
second
studi
conduct
adult
random
receiv
three
dose
idv
alon
mg
dna
idv
mg
aluminum
adjuv
mg
placebo
seriou
advers
event
attribut
idv
vaccin
adjuv
report
viru
neutral
vn
hemagglutin
inhibit
hai
antibodi
observ
minor
subject
three
vaccin
idv
alon
hai
respons
follow
inactiv
vaccin
suggest
prime
idv
modest
vn
hai
antibodi
respons
observ
vaccin
idv
aluminum
adjuv
great
deal
work
dna
vaccin
need
achiev
robust
ctl
antibodi
respons
problemat
man
safeti
concern
includ
genom
integr
gener
antidna
antibodi
optim
dose
deliveri
method
role
adjuv
clear
rsv
liveattenu
coldpassag
cp
temperaturesensit
ts
vaccin
viru
sequenc
analysi
show
cold
passag
chemic
mutagenesi
introduc
three
nucleotid
substitut
two
l
protein
third
gene
mutat
skiadopoulo
et
al
detail
studi
found
mutat
l
specifi
signific
reduct
plaqu
format
respons
intermedi
attenu
mice
contrast
l
mutat
contribut
temperatur
sensit
attenu
phenotyp
unexpectedli
mutat
alon
specifi
complet
restrict
plaqu
format
high
level
attenu
mice
thu
viru
contain
set
temperatur
sensit
nontemperatur
sensit
mutat
account
genet
stabil
recombin
version
viru
phenotyp
indistinguish
repres
background
addit
mutat
introduc
obtain
desir
level
attenu
current
rsv
vaccin
candid
fail
infect
seroposit
children
age
month
vaccin
safe
genet
stabl
seroneg
children
age
month
dose
pfu
plaqu
form
unit
two
dose
administ
infant
base
detect
viru
shed
one
dose
infecti
infant
two
isol
postimmun
show
reduct
temperatur
sensit
phenotyp
either
inoculum
vaccin
caus
mild
moder
nasal
congest
lower
respiratori
tract
symptom
despit
high
level
nasopharyng
replic
second
inocul
viru
shed
detect
four
case
preliminari
result
suggest
protect
occur
absenc
detect
serum
igg
antibodi
respons
howev
presenc
respiratori
symptom
suggest
attenu
vaccin
necessari
infant
second
deriv
bear
addit
ts
mutat
temperatur
sensit
attenu
parent
clinic
trial
viru
initi
whitehead
et
al
much
inform
necessari
assess
potenti
valu
rsv
vaccin
adult
lack
knowledg
protect
immun
epidemiolog
appropri
target
popul
limit
unlik
infant
rapid
antigen
test
cultur
insensit
detect
rsv
infect
adult
howev
increas
evid
suggest
rsv
major
pathogen
elderli
adult
particularli
underli
cardiopulmonari
condit
immunocompromis
host
sinc
outbreak
rsv
infect
nurs
home
popul
report
experiment
challeng
studi
adult
suggest
resist
infect
correl
titer
serum
mucos
rsv
neutral
antibodi
observ
casecontrol
studi
elderli
adult
suggest
sever
ill
invers
correl
level
humor
immun
infect
elderli
fourfold
lower
titer
serum
neutral
antibodi
control
thu
far
three
candid
vaccin
approv
phase
ii
test
elderli
adult
includ
purifi
fusion
protein
subunit
vaccin
pfp
chimer
subunit
fg
fusionattach
protein
vaccin
liveattenu
cold
passag
temperaturesensit
cpt
mutant
viru
phase
safeti
immunogen
test
pfp
vaccin
involv
elderli
adult
intramuscular
inject
well
toler
recipi
fourfold
greater
respons
f
protein
elisa
fourfold
greater
neutral
antibodi
respons
subsequ
studi
frail
elderli
nurs
home
resid
found
antibodi
respons
vaccine
respect
healthi
elderli
year
age
older
respons
respect
evalu
clinic
endpoint
necessari
reinfect
rsv
associ
consider
reduct
ill
sever
henderson
et
al
matern
antibodi
rsv
passiv
acquir
fetu
shown
protect
lower
respiratori
tract
ill
anim
model
studi
demonstr
potenti
benefit
passiv
administ
rsv
immunoglobulin
princ
et
al
siber
et
al
subsequ
trial
human
murin
monoclon
antibodi
direct
f
protein
yield
differ
result
cotton
rat
model
protect
rsv
lung
infect
achiev
passiv
transfer
antibodi
graham
et
al
primat
human
ivig
administ
local
systemat
effect
reduc
titer
viru
recov
lung
nose
polyclon
prepar
high
titer
neutral
antibodi
shown
provid
protect
sever
rsv
ill
prematur
infant
children
bronchopulmonari
dysplasia
hem
et
al
prevent
studi
group
one
monoclon
antibodi
prepar
shown
effect
prevent
hospit
rsv
prematur
infant
children
bronchopulmonari
dysplasia
random
studi
among
children
prematur
bronchopulmonari
dysplasia
palivizumab
result
reduct
hospit
rsv
placebo
group
vs
palivizumab
group
effect
mainli
observ
subgroup
infant
prematur
vs
respect
less
signific
children
bronchopulmonari
dysplasia
alon
vs
respect
impactrsv
studi
group
anoth
monoclon
antibodi
provid
protect
effect
possibl
lower
neutral
activ
consid
high
cost
prepar
prophylaxi
consid
highrisk
patient
children
less
year
age
chronic
lung
diseas
possibl
prematur
infant
week
less
rsv
season
although
prophylaxi
shown
efficaci
treatment
prepar
appear
less
promis
hem
et
al
earli
trial
found
human
ivig
treatment
appear
reduc
viru
shed
improv
oxygen
satur
young
infant
hospit
rsv
infect
howev
rsvig
contain
high
titer
neutral
antibodi
rsv
reduc
pulmonari
viru
titer
improv
clinic
outcom
day
hospit
use
icu
need
intub
hospit
infant
rodriguez
et
al
recent
studi
monoclon
antibodi
rsv
f
protein
intub
children
found
similar
neg
result
result
indic
treatment
polyclon
monoclon
rsv
antibodi
prepar
infant
establish
lower
respiratori
tract
diseas
alter
symptom
overal
outcom
understand
bronchiol
improv
appear
strategi
target
viru
shed
alon
limit
result
remain
determin
whether
earli
treatment
upper
respiratori
tract
rsv
ill
prevent
progress
lower
respiratori
tract
diseas
human
parainfluenza
virus
particularli
import
caus
hospit
infant
children
attack
rate
lower
respiratori
ill
higher
infant
younger
month
age
consequ
prophylaxi
given
earli
life
effect
presenc
matern
antibodi
natur
infect
piv
prevent
reinfect
protect
sever
diseas
suggest
multipl
dose
vaccin
may
necessari
signific
antigen
drift
occur
monoval
vaccin
protect
option
vaccin
stimul
humor
mucos
cellmedi
immun
natur
infect
phase
clinic
trial
bovin
parainfluenza
type
live
intranas
vaccin
conduct
subject
particip
includ
infant
children
adult
receiv
tcid
tissu
cultur
infecti
dose
intranas
vaccin
appear
safe
among
seroneg
children
month
age
infect
recipi
develop
level
antibodi
consid
protect
vaccin
conserv
phenotyp
replic
vaccine
transmiss
singl
dose
vaccin
infect
infant
less
month
age
induc
seroconvers
recipi
random
doubleblind
phase
studi
differ
dosag
ongo
infant
less
month
age
enrol
immun
intranas
spray
month
placebo
tcid
sideeffect
mainli
respiratori
complaint
observ
patient
combin
studi
group
serum
hemagglutin
inhibit
hai
seroconvers
observ
infant
vaccin
group
compar
placebo
group
viru
shed
identifi
vaccin
recipi
versu
placebo
recipi
proport
seroconvers
vaccin
group
placebo
result
show
live
intranas
bovin
piv
type
vaccin
infecti
immunogen
observ
protect
efficaci
await
liveattenu
human
candid
vaccin
found
safe
immunogen
phenotyp
stabl
infant
genet
basi
temperatur
sensit
cold
adapt
attenu
phenotyp
defin
genet
stabil
shown
skiadopoulo
et
al
cdnabas
recombin
contain
mutat
construct
shown
three
mutat
l
polymeras
protein
confer
temperatur
sensit
attenu
phenotyp
tao
et
al
recombin
possess
mutat
except
l
temperatur
sensit
attenu
hamster
find
indic
multipl
mutat
within
genom
contribut
phenotyp
composit
phenotyp
multipl
genet
alter
contribut
attenu
stabil
exist
wild
type
attenu
virus
made
possibl
gener
live
attenu
viru
code
sequenc
hemagglutininneuraminidas
fusion
protein
replac
genom
background
viru
bear
major
protect
antigen
deriv
carri
temperatur
sensit
chang
l
gene
live
attenu
viru
also
construct
infect
hamster
viru
call
gener
moder
level
antibodi
complet
resist
challeng
wild
type
thu
revers
genet
system
use
success
rapidli
creat
liveattenu
vaccin
candid
neuraminidas
surfac
glycoprotein
possess
enzymat
activ
essenti
replic
influenza
b
virus
hayden
gwaltney
neuraminidas
tetramet
activ
enzym
site
locat
within
pocket
surfac
glycoprotein
subunit
activ
site
highli
conserv
across
influenza
b
virus
enzym
respons
cleavag
bond
exist
neuramin
acid
adjac
sugar
residu
main
action
enzym
promot
virion
releas
infect
cell
prevent
viru
aggreg
action
also
prevent
inactiv
influenza
viru
respiratori
mucu
facilit
spread
within
respiratori
tract
least
one
type
influenza
neuraminidas
also
bind
plasminogen
contribut
ha
cleavag
activ
certain
strain
base
crystallograph
structur
na
two
neuraminidas
inhibitor
reach
advanc
clinic
develop
inhal
zanamivir
oral
ethyl
ester
prodrug
activ
compound
zanamivir
oral
bioavail
less
poorli
distribut
respiratori
tract
intraven
administr
anim
part
rapid
renal
elimin
administ
inhal
human
approxim
drug
reach
lower
airway
deposit
pharynx
estim
absolut
bioavail
inhal
zanamivir
efthymiopoulo
et
al
inhal
zanamivir
well
toler
without
known
signific
sideeffect
experiment
infect
studi
anim
human
shown
protect
effect
topic
zanamivir
experiment
human
influenza
zanamivir
given
intranas
effect
prevent
infect
effect
prevent
febril
ill
hayden
et
al
earli
treatment
shown
decreas
viru
titer
nasal
wash
decreas
symptom
intraven
administr
experiment
human
infect
also
highli
protect
protect
efficaci
inhal
zanamivir
test
healthi
ambulatori
adult
influenza
outbreak
influenza
viru
circul
commun
inhal
zanamivir
daili
placebo
week
initi
monto
et
al
efficaci
antivir
prevent
laboratori
confirm
clinic
influenza
ill
efficaci
prevent
influenza
infect
without
symptom
potenti
role
season
prophylaxi
like
restrict
highrisk
patient
vaccin
like
ineffect
due
antigen
chang
poor
host
immun
respons
postexposur
prophylaxi
facil
use
inhal
zanamivir
prevent
nosocomi
influenza
nurs
home
studi
zanamivir
also
demonstr
therapeut
activ
treat
acut
uncompl
influenza
adult
healthi
adult
natur
influenza
zanamivir
given
intranas
spray
plu
inhal
inhal
alon
compar
placebo
hayden
et
al
zanamivir
treatment
provid
signific
decreas
median
time
allevi
key
influenza
symptom
day
vs
day
placebo
group
subgroup
patient
febril
ill
symptom
less
h
reduct
time
allevi
major
symptom
anoth
recent
trial
confirm
observ
found
clinic
benefit
reduc
risk
complic
highrisk
patient
underli
pulmonari
diseas
mist
studi
group
control
clinic
trial
nebul
zanamivir
hospit
patient
influenza
lower
respiratori
tract
diseas
underway
also
shown
clinic
activ
prevent
treat
acut
influenza
activ
compound
poorli
absorb
bioavail
parent
prodrug
good
follow
oral
ingest
oral
bioavail
reduc
food
plasma
halflif
h
infrequ
dose
feasibl
gener
well
toler
associ
upper
gastrointestin
upset
adult
acut
influenza
larg
prevent
administr
food
provid
protect
experiment
influenza
infect
anim
human
studi
hayden
et
al
also
recent
show
protect
natur
occur
influenza
administ
week
healthi
work
adult
popul
aoki
et
al
hayden
et
al
daili
administr
mgday
associ
protect
efficaci
influenza
ill
among
young
healthi
adult
suffer
natur
influenza
oral
treatment
shorten
median
durat
symptom
day
placebo
group
group
receiv
one
two
dose
associ
reduct
symptom
sever
importantli
treatment
associ
reduct
physiciandiagnos
complic
requir
antibiot
studi
oral
treat
influenza
children
elderli
highrisk
adult
progress
passag
influenza
virus
cell
cultur
presenc
zanamivir
eventu
lead
emerg
resist
mutant
howev
select
resist
variant
requir
consider
effort
amantadin
rimantadin
genotyp
analysi
mutant
indic
mutat
either
major
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
confer
resist
class
compound
common
mutat
observ
neuraminidas
gli
substitut
glu
residu
residu
interact
directli
guanidino
moieti
zanamivir
substitut
residu
catalyt
site
found
vitro
neuraminidas
bear
mutat
reduc
sensit
zanamivir
neuraminidas
inhibit
assay
howev
variant
either
reduc
enzym
activ
stabil
vitro
select
zanamivirresist
mutant
possess
mutat
neuraminidas
also
demonstr
reduc
infect
test
mice
mutat
identifi
ha
resid
close
proxim
receptor
bind
site
result
reduct
viru
affin
cellular
receptor
variant
decreas
depend
neuraminidas
activ
releas
infect
cell
mechan
resist
independ
neuraminidas
activ
ha
mutant
demonstr
crossresist
neuraminidas
inhibitor
cell
cultur
one
ha
mutant
resist
vitro
fulli
sensit
zanamivir
mice
impact
ha
mutat
pathogen
zanamivirresist
influenza
virus
human
remain
determin
recent
influenza
b
viru
repeatedli
isol
immunocompromis
child
pneumonia
despit
exposur
nebul
zanamivir
week
gubareva
et
al
ha
mutat
thr
ile
detect
day
treatment
mutat
abolish
glycosyl
site
close
proxim
ha
receptor
bind
site
reduc
viru
affin
ha
mutat
follow
mutat
neuraminidas
activ
site
viru
arg
ly
arg
function
residu
directli
interact
sialic
acid
moieti
particip
substrat
bind
mutat
led
reduct
enzym
sensit
zanamivir
mutant
enzym
activ
enzym
activ
vitro
compar
wild
type
viru
man
ferret
share
similar
specif
receptor
present
respiratori
tract
epithelium
challeng
ferret
done
experi
shown
growth
prefer
parent
viru
mutant
untreat
although
zanamivirtr
ferret
addit
mutant
viru
demonstr
reduc
virul
greater
quantiti
mutant
viru
requir
establish
product
infect
ferret
compar
parent
nasal
wash
viru
titer
cell
count
protein
level
lower
anim
infect
mutant
viru
viru
variant
behav
like
wild
type
viru
suggest
differ
receptor
use
mdck
cell
vivo
ha
mutat
impact
exampl
influenza
b
viru
immunocompromis
child
sensit
standard
assay
mdck
cell
mutant
viru
increas
affin
mdck
cell
receptor
combin
reduc
neuraminidas
activ
render
viru
sensit
zanamivir
cell
cultur
data
indic
current
method
monitor
resist
mutant
potenti
flaw
due
absenc
cell
cultur
system
adequ
reflect
human
respiratori
tract
epithelium
neuraminidas
inhibit
assay
detect
emerg
zanamivirresist
mutant
virus
possess
resist
enzym
practic
method
monitor
ha
na
mutat
convey
resist
need
influenza
lead
caus
death
elderli
rank
third
fifth
caus
death
adult
year
age
clinic
present
popul
specif
fever
occur
case
influenza
elderli
patient
annual
influenza
vaccin
decreas
rate
lower
respiratori
tract
diseas
hospit
death
nurs
home
influenza
vaccin
estim
effect
frail
nurs
home
resid
patriarca
et
al
prospect
surveil
document
annual
outbreak
influenza
despit
resid
vaccin
rate
recommend
advisori
committe
immun
practic
influenza
outbreak
control
program
includ
antivir
chemoprophylaxi
limit
influenza
outbreak
nurs
home
advisori
committe
immun
practic
effect
short
durat
prophylaxi
nurs
home
influenza
outbreak
test
studi
rural
home
veteran
volunt
random
short
durat
minimum
day
last
case
facil
long
durat
minimum
day
last
case
facil
amantadin
rimantadin
outbreak
influenza
drinka
et
al
criteria
influenza
outbreak
met
year
total
cultureconfirm
case
identifi
day
case
identifi
day
case
identifi
day
particip
develop
influenza
termin
shortor
longterm
prophylaxi
despit
persist
influenza
commun
antivir
chemoprophylaxi
effect
control
nurs
home
influenza
outbreak
administ
period
day
beyond
last
cultureconfirm
influenza
case
nurs
home
howev
amantadineresist
strain
identifi
resid
seven
develop
ill
prophylaxi
six
receiv
antivir
medic
addit
retrospect
chart
review
found
twoto
fourfold
increas
fall
agit
confus
amantadin
administr
placebo
control
trial
show
rimantadin
associ
increas
number
signific
health
event
includ
death
studi
longterm
use
rimantadin
season
prophylaxi
nurs
home
monto
et
al
experi
highlight
need
altern
antivir
agent
prospect
random
unblind
pilot
studi
perform
examin
safeti
efficaci
zanamivir
influenza
outbreak
control
nurs
home
schill
et
al
chemoprophylaxi
zanamivir
compar
standard
care
sequenti
influenza
influenza
b
outbreak
bed
nurs
home
total
volunt
four
epidem
unit
random
zanamivir
volunt
random
rimantadin
two
epidem
unit
day
prophylaxi
four
new
febril
respiratori
ill
detect
one
volunt
receiv
rimantadin
develop
influenza
anoth
studi
volunt
two
unit
influenza
b
outbreak
random
receiv
zanamivir
volunt
one
epidem
unit
random
drug
day
prophylaxi
one
new
febril
respiratori
ill
detect
seriou
advers
event
occur
larg
multicent
doubleblind
random
control
trial
underway
investig
efficaci
safeti
inhal
zanamivir
control
nurs
home
influenza
outbreak
despit
synthesi
ribavirin
nearli
year
ago
precis
mechan
action
remain
incomplet
understood
ribavirin
exert
antivir
effect
via
inhibit
inosin
monophosph
dehydrogenas
result
reduct
guanosin
triphosph
gtp
pool
necessari
transcript
virus
drug
also
appear
interfer
cap
mrna
therebi
inhibit
gtpdepend
mrna
transcript
furthermor
ribavirin
shown
directli
inhibit
initi
elong
virusspecif
rna
polymeras
emerg
resist
occur
ribavirin
administr
adapt
inhal
develop
small
particl
b
mm
aerosol
gener
spag
small
water
aerosolcontrol
studi
infant
hospit
rsv
bronchiol
pneumonia
led
licensur
drug
rsv
diseas
children
use
ribavirin
young
infant
becom
increasingli
controversi
due
lack
larg
clinic
random
trial
appropri
control
show
effect
clinic
relev
endpoint
concern
regard
bronchospasm
exposur
health
worker
high
cost
also
contribut
decreas
use
aerosol
ribavirin
becom
decreasingli
util
otherwis
healthi
pediatr
patient
use
immunocompromis
patient
continu
unfortun
control
studi
treatment
rsv
highrisk
immunocompromis
patient
undertaken
compar
histor
control
use
ribavirin
monotherapi
adult
bone
marrow
transplant
indic
benefit
addit
ivig
aerosol
ribavirin
associ
mortal
rsv
pneumonia
less
histor
control
intraven
ribavirin
seem
associ
benefit
rsv
pneumonia
ribavirin
given
earli
radiolog
sign
seem
associ
benefit
treat
rsv
infect
immunocompromis
host
potenti
preemptiv
therapi
preventtreat
rsv
diseas
bmt
patient
investig
prospect
blind
placebocontrol
trial
auspic
collabor
antivir
studi
group
casg
benefit
ribavirin
probabl
exist
treatment
given
earli
high
dosag
ribavirin
licens
treatment
influenza
although
demonstr
effect
colleg
student
one
trial
found
littl
benefit
children
hospit
influenza
ribavirin
demonstr
effect
given
intraven
system
hemorrhag
fever
lassa
fever
hantaan
hemorrag
fever
renal
syndrom
instanc
larg
well
control
clinic
trial
conduct
util
mortal
clinic
endpoint
case
report
efficaci
describ
crimeancongo
hemorrhag
fever
viru
sin
nombr
viru
hantaviru
pulmonari
syndrom
ribavirin
reason
activ
vitro
measl
adenovirus
clinic
report
mainli
immunocompromis
host
uncontrol
ribavirin
also
test
bmt
patient
piv
infect
without
show
obviou
clinic
benefit
picornaviridia
famili
consist
serotyp
associ
common
cold
asept
mening
conjunct
enceph
respiratori
diseas
human
rhinovirus
includ
differ
serotyp
effect
therapi
current
avail
sever
new
compound
develop
rhinoviru
proteas
respons
cleavag
viral
precursor
polyprotein
structur
enzymat
protein
dna
sequenc
comparison
among
rhinoviru
serotyp
even
among
sever
relat
picornavirus
identifi
signific
degre
homolog
within
code
region
includ
strict
conserv
activ
site
residu
resolut
threedimension
structur
xray
crystallographi
demonstr
proteas
polypeptid
backbon
serin
proteas
activesit
nucleophil
compris
cystein
sulfhydryl
irrevers
peptidomimet
inhibitor
proteas
cell
protect
assay
inhibit
replic
rhinoviru
serotyp
mean
ec
nm
inhibit
also
replic
relat
picornavirus
includ
coxsackievirus
enteroviru
echoviru
cytotox
dose
mm
yield
high
therapeut
indic
direct
inhibit
proteolyt
activ
show
dosedepend
accumul
viral
precursor
polyprotein
reduct
process
protein
product
treatment
rhinoviru
infect
human
bronchial
epitheli
cell
line
result
dosedepend
reduct
infecti
virus
well
elabor
vitro
efficaci
compar
favor
drug
develop
pleconaril
antiproteas
poorli
absorb
nasal
formul
develop
clinic
studi
expect
near
futur
pleconaril
oral
compound
activ
picornavirus
name
rhinovirus
coxsackievirus
echovirus
mechan
action
agent
bind
capsid
viru
inhibit
attach
viru
uncoat
vitro
sensit
rhinovirus
coxsacki
echovirus
gener
mgml
pleconaril
well
absorb
bioavail
singl
oral
dose
mg
plasma
concentr
mgml
pharmacokinet
profil
similar
adult
children
pleconaril
lipophil
anim
studi
concentr
mening
nasal
epithelium
greater
plasma
experiment
infect
studi
coxsacki
viru
done
patient
random
receiv
mg
pleconaril
placebo
begin
viru
exposur
patient
receiv
oral
pleconaril
symptom
observ
compar
placebo
although
subject
becom
infect
phase
studi
complet
patient
viral
mening
pcr
viru
posit
case
durat
diseas
shorter
treatment
group
compar
placebo
group
day
versu
day
among
pediatr
patient
enteroviru
mening
signific
decreas
global
score
morbid
better
clinic
recoveri
found
placebocontrol
trial
open
label
compassion
studi
suggest
pleconaril
provid
clinic
benefit
among
agammaglobulinem
patient
chronic
enteroviru
enceph
control
clinic
trial
evalu
oral
pleconaril
adult
includ
asthmat
patient
children
suspect
rhinoviru
diseas
progress
intracellular
adhes
molecul
icam
shown
major
receptor
rhinovirus
solubl
specif
inhibitor
rhinoviru
replic
monkey
solubl
prevent
infect
rhinovirus
human
infect
rhinoviru
intranas
solubl
shown
decreas
viru
titer
prevent
cold
symptom
howev
effect
signific
develop
stop
virusspecif
fusion
protein
mediat
virion
membran
fusion
host
cell
infect
cell
uninfect
cell
protein
requir
viru
infect
spread
within
host
white
synthet
peptid
deriv
predict
region
within
transmembran
protein
potent
inhibitor
viral
fusion
infect
vitro
wild
et
al
one
peptid
deriv
domain
alreadi
demonstr
inhibit
replic
human
trial
base
amino
acid
motif
activ
peptid
transmenbran
protein
similar
protein
sequenc
sought
fusogen
protein
procedur
use
computer
antifus
search
technolog
allow
identif
similar
domain
viral
sequenc
swissprot
databas
strategi
accur
predict
sequenc
surfac
glycoprotein
fusogen
virus
includ
hiv
influenza
hepat
b
c
paramyxovirus
lambert
et
al
paramyxovirus
contain
two
major
surfac
glycoprotein
receptor
bind
protein
hn
parainfluenza
h
measl
g
rsv
facilit
attach
cell
fusion
protein
requir
releas
genomecontain
nucleocapsid
cell
host
cytoplasm
joshi
et
al
research
identifi
activ
peptid
within
heptad
repeat
domain
fusion
protein
rsv
domain
includ
predict
helic
sequenc
identifi
retrovirus
share
sever
properti
domain
activ
protein
seem
specif
without
cross
reactiv
yao
compan
activ
peptid
antivir
ec
valu
paramyxovirus
rang
mm
infect
fusion
inhibit
vitro
associ
cellular
cytox
identifi
rsv
peptid
heptad
repeat
domain
vivo
efficaci
cotton
rat
model
rsv
infect
accumul
literatur
activ
peptid
fusogen
protein
strengthen
concept
function
similar
domain
exist
retroviru
orthomyxoviru
paramyxoviru
fusion
protein
viral
respiratori
tract
infect
lead
caus
morbid
mortal
worldwid
mani
instanc
rtpcr
shown
frequenc
respiratori
tract
infect
associ
particular
respiratori
virus
higher
suspect
techniqu
establish
common
respiratori
virus
princip
caus
acut
otiti
media
sinus
asthmat
exacerb
associ
excess
use
antibiot
presum
bacteri
infect
contribut
health
care
cost
foster
emerg
resist
bacteria
certain
popul
particularli
elderli
transplant
leukemia
patient
asthma
underli
lung
diseas
particular
risk
sever
diseas
due
common
respiratori
virus
outbreak
influenza
virus
hong
kong
remind
us
threat
new
deadli
influenza
pandem
ever
present
molecular
studi
show
influenza
viru
avian
strain
transmit
human
without
intermedi
host
contain
threaten
outbreak
achiev
destruct
domest
poultri
reservoir
viru
outbreak
emphas
need
support
effect
public
health
program
continu
influenza
surveil
clinic
syndrom
sever
ill
manifest
respiratori
viral
infect
reflect
differ
virul
among
differ
respiratori
virus
host
respons
observ
pathogenesi
rsv
infect
shown
host
immun
respons
contribut
clinic
manifest
develop
bronchiol
clinic
trial
suggest
antivir
may
suffici
control
diseas
process
complex
redund
cytokin
network
indic
inform
need
dynam
pattern
host
inflammatori
respons
divers
syndrom
like
common
cold
influenza
bronchiol
sever
rapid
diagnost
test
influenza
b
virus
base
detect
nucleoprotein
neuraminidas
activ
variou
stage
develop
clinic
use
specif
test
gener
good
sensit
variabl
depend
type
sampl
age
patient
rapid
assay
use
surveil
convent
cultur
necessari
identifi
circul
influenza
strain
new
class
antivir
drug
effect
influenza
b
virus
advanc
clinic
develop
neuraminidas
inhibitor
name
inhal
zanamivir
oral
proven
effect
drug
reduc
symptom
potenti
reduc
risk
complic
acut
influenza
infect
prevent
influenza
healthi
adult
effect
prophylaxi
use
epidem
period
agent
could
provid
use
adjunct
vaccin
prevent
result
ongo
studi
elderli
immunocompromis
host
children
influenza
associ
signific
morbid
mortal
await
interest
influenza
viru
strain
resist
neuraminidas
inhibitor
select
vitro
resist
result
mutat
ha
neuraminidas
gene
occur
prolong
exposur
drug
vitro
observ
cell
cultur
experiment
infect
anim
indic
neuraminidas
variant
replic
less
well
wild
type
strain
resist
variant
nove
detect
clinic
use
signific
neuraminidas
resist
strain
need
evalu
effect
antivir
agent
need
number
respiratori
viral
pathogen
although
aerosol
ribavirin
use
hospit
children
efficaci
treat
rsv
bronchiol
controversi
better
agent
need
agent
proven
valu
current
avail
rhinoviru
coronaviru
piv
adenoviru
infect
pleconaril
antipicornaviru
capsidbind
agent
shown
promis
preliminari
result
treat
enteroviru
mening
clinic
studi
ongo
presum
rhinoviru
infect
involv
asthmat
otherwis
healthi
person
inhibitor
proteas
rhinoviru
identifi
clinic
studi
use
topic
appli
antiproteas
agent
expect
near
futur
liveattenu
coldadapt
influenza
vaccin
repres
major
clinic
advanc
trival
formul
influenza
vaccin
shown
highli
protect
influenza
ill
associ
complic
children
season
also
found
protect
drift
variant
children
adult
costeffect
annual
vaccin
healthi
adult
clearli
establish
global
health
strategi
probabl
continu
focu
mainli
improv
vaccin
highrisk
popul
use
molecular
biolog
allow
construct
recombin
coldadapt
attenu
rsv
virus
elicit
good
immun
respons
clinic
studi
ongo
young
infant
children
phase
ii
studi
use
live
intranas
bovin
piv
type
vaccin
also
conduct
children
adult
clinic
trial
ongo
contrast
initi
result
adjuv
dna
vaccin
influenza
indic
need
investig
develop
immunogen
formul
